Advertisement




Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Lymphoma

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement



Advertisement